210992-85-1

Basic information

• Product Name: 4-Chloro-6-(phenylmethoxy)-2-pyrimidinamine
• Synonyms: 4-Chloro-6-(phenylmethoxy)-2-pyrimidinamine;4-(benzyloxy)-6-chloropyrimidin-2-amine
• CAS NO: 210992-85-1
• Molecular Formula: C₁₁H₁₀ClN₃O
• Molecular Weight: 235.67
• Mol File: 210992-85-1.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 448.471 °C at 760 mmHg
• Flash Point: 225.028 °C
• Appearance: /
• Density: 1.348 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.637
• CAS DataBase Reference: 4-Chloro-6-(phenylmethoxy)-2-pyrimidinamine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Chloro-6-(phenylmethoxy)-2-pyrimidinamine(210992-85-1)
• EPA Substance Registry System: 4-Chloro-6-(phenylmethoxy)-2-pyrimidinamine(210992-85-1)

Safety Data

• Hazardous Substances Data: 210992-85-1(Hazardous Substances Data)

Usage

General Description

4-Chloro-6-(phenylmethoxy)-2-pyrimidinamine is a chemical compound with a molecular formula C11H9ClN4O. It is a pyrimidinamine derivative with a chloro group at the 4th position and a phenylmethoxy group at the 6th position on the pyrimidine ring. 4-Chloro-6-(phenylmethoxy)-2-pyrimidinamine has potential applications in the pharmaceutical industry, particularly in the development of novel drugs or as a building block for medicinal chemistry research. Its structure suggests that it may have biological activity and could be used in the synthesis of new pharmaceuticals. Further research and testing are needed to understand its potential uses and effects.

InChI:InChI=1/C11H10ClN3O/c12-9-6-10(15-11(13)14-9)16-7-8-4-2-1-3-5-8/h1-6H,7H2,(H2,13,14,15)

Upstream product

• 56-05-3 2-Amino-4,6-dichloropyrimidine 
• 100-51-6 benzyl alcohol 

Downstream Products

• 915411-38-0 [4-benzyloxy-6-(1-triisopropylsilanyl-1H-indol-4-yl)-pyrimidin-2-yl]-pyridin-3-yl-amine 

Relevant articles and documents

Heterocyclic compounds as well as preparation method and application thereof

The invention belongs to the field of medicines and particularly relates to heterocyclic compounds with the structural characteristics shown in formula (I) or pharmaceutically acceptable salts, a preparation method and an application of the heterocyclic compounds as a nucleotide oxidative damage repairase MTH1 inhibitor. Pharmacological experiment results indicate that the compounds have significant inhabitation effects on the activity of MTH1 and can be used for preventing and treating clinical diseases related to MTH1.

Anti-cancer agents and uses thereof

The present invention is in the area of novel compounds and salts thereof, their syntheses, and their use as anti-cancer agents. The compounds include compounds of Formula I: and solvates, hydrates and pharmaceutically-acceptable salts thereof, wherein A1 is N or CR1; A3 is N or CR3; A5 is N or CR5; R1, R3-R6 and L are defined in the specification; n is 0 or 1; and X is an optionally-substituted aryl group having 6-10 carbons in the ring portion, an optionally-substituted 6-membered heteroaryl group having 1-3 nitrogen atoms in the ring portion, an optionally-substituted 5-membered heteroaryl group having 0-4 nitrogen atoms in the ring portion and optionally having 1 sulfur atom or 1 oxygen atom in the ring portion, or an optionally-substituted heteroaryl group in which a 6-membered ring is fused either to a 5-membered ring or to a 6-membered ring, wherein in each case 1, 2, 3 or 4 ring atoms are heteroatoms independently selected from nitrogen, oxygen and sulfur. They are effective against a broad range of cancers, especially leukemia, prostate, non-small cell lung and colon. They are additionally useful in the treatment of proliferative retinopathies such as diabetic neuropathy and macular degeneration.

Anti-cancer agents and uses thereof

The present invention is in the area of novel compounds and salts thereof, their syntheses, and their use as anti-cancer agents. The compounds include compounds of Formula I: and solvates, hydrates and pharmaceutically-acceptable salts thereof, wherein A1 is N or CR1; A3 is N or CR3; A5 is N or CR5; R1, R3—R6 and L are defined in the specification; n is 0 or 1; and X is an optionally-substituted aryl group having 6-10 carbons in the ring portion, an optionally-substituted 6-membered heteroaryl group having 1-3 nitrogen atoms in the ring portion, an optionally-substituted 5-membered heteroaryl group having 0-4 nitrogen atoms in the ring portion and optionally having 1 sulfur atom or 1 oxygen atom in the ring portion, or an optionally-substituted heteroaryl group in which a 6-membered ring is fused either to a 5-membered ring or to a 6-membered ring, wherein in each case 1, 2, 3 or 4 ring atoms are heteroatoms independently selected from nitrogen, oxygen and sulfur. They are effective against a broad range of cancers, especially leukemia, non-small cell lung and colon.